Cellestia is a privately owned, clinical-stage (Phase I) biopharma company giving hope to cancer patients with limited or no treatment options by developing innovative targeted therapies. Founded in 2014, the company has built a proprietary drug discovery platform based on a unique mode of action that targets protein–protein interactions (PPI) with small molecules, combined with companion diagnostics to deliver first-in-class solutions for NOTCH-driven cancers. Its lead clinical candidate, CB-103, targets orphan indications such as adenoid cystic carcinoma of the salivary gland and a subtype of childhood leukemia, while also being developed for larger cancer indications including breast cancer. At the same time, Cellestia continues to expand its pipeline through the development of novel PPI inhibitors for additional oncology indications, guided by an experienced team of scientists, drug developers, and business professionals.